EN
Malignant tumors are complex polygenic diseases with significant heterogeneity in genomic profiles across individuals and cancer types. A large number of patients with solid tumors are in urgent need of individualized treatment regimens. With the rapid advancement of targeted drugs and immunotherapy, authoritative guidelines, including NCCN and CSCO consistently recommend comprehensive genetic testing for patients with advanced solid tumors to identify actionable driver variants.
Leveraging proprietary RingCap® technology, Xiamen Spacegen Biotech launches the Solid Tumor 107-Gene Test (Bupreen). A single assay covers core genes related to targeted therapy, immunotherapy, and chemotherapy, simultaneously identifying mutations, insertions/deletions, gene fusions and MSI. Detecting both common targets and rare driver variants, it allows clinicians to perform molecular subtyping, treatment selection and resistance mechanism analysis in one stop, building an efficient and reliable precision oncology solution for patients with diverse solid tumors.
1.Newly diagnosed solid tumor patients. Testing prior to targeted, immunotherapy and chemotherapy assists clinicians in treatment planning and prognostic evaluation.
2.Solid tumor patients with acquired resistance to targeted therapy or failed chemotherapy who require alternative regimens. Genetic testing identifies resistance mechanisms and discovers new actionable variants.
Simple & Rapid
Built on proprietary RingCap® technology, library Preparation takes just 2 steps with a theoretical duration of 3.5 hours
Precise Detection
Dual DNA+RNA NGS testing boosts fusion detection yield and expands beneficiaries of targeted therapy
High Sensitivity
Identifies mutations ≥1% VAF in DNA samples and fusion variants ≥20 copies/μL in RNA samples
Comprehensive Coverage
Encompasses clinically critical solid tumor genes and multiple variant forms (mutation, amplification, rearrangement/fusion) to satisfy all-round clinical testing needs
Quality Assurance
Rigorous QC criteria applied across nucleic acid extraction, library preparation and raw data output
1. Nucleic Acid Extraction
2. Library Preparation
3. Sequencing
4. One-stop Data Analysis
5. Report Generation
闽公网安备35021202000745